Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Recap: PLBY Group Q4 Earnings

PLBY Group (NASDAQ:PLBY) reported its Q4 earnings results on Wednesday, March 27, 2024 at 04:05 PM. Here’s what…
byBenzinga Insights
March 27, 2024
1 minute read
Total
0
Shares
0
0
0
0
0
0

PLBY Group (NASDAQ:PLBY) reported its Q4 earnings results on Wednesday, March 27, 2024 at 04:05 PM.

Here’s what investors need to know about the announcement.

Earnings

PLBY Group beat estimated earnings by 64.0%, reporting an EPS of $-0.05 versus an estimate of $-0.14.

Revenue was down $29.15 million from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.09 which was followed by a 25.0% drop in the share price the next day.

Here’s a look at PLBY Group’s past performance:

Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022
EPS Estimate -0.13 -0.11 -0.17 -0.17
EPS Actual -0.22 -0.05 -0.58 -0.22
Revenue Estimate 32.48M 48.84M 56.48M 75.56M
Revenue Actual 33.28M 35.10M 51.44M 68.52M

To track all earnings releases for PLBY Group visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

CBD-Focused Pharma Co. Innocan Reveals 433% YoY Increase In 2023 Revenue As It Pursues FDA Approval

By Jelena Martinovic
February 13, 4:22 PM
Cannabinoid-focused pharmaceutical company Innocan Pharma Corp expects preliminary revenues of $4.89m in Q4 of fiscal 2023, representing a YoY increase of 331%. It said preliminary revenues are expected to be at least $13.6m for the whole of the fiscal year, a 433% YoY increase. Its subsidiary B.I. Sky Global drove the increase in sales. Innocan is currently pursuing FDA approval for its human pharmaceutical applications following successful pre-clinical trials, and the company expects pre-investigational new drug applications to be submitted to the FDA before the end of the month. Innocan has developed a long-lasting and therapeutic liposomal formulation for CBD called LPT Solution, which administers injectable CBD encapsulated in liposomes to achieve long-lasting therapeutic levels of CBD in the body. The company said the technology creates a more effective and prolonged therapeutic effect. Innocan plans to test the LPT platform on a new animal species in the near future.

CSE:INNO